Gewinn- und Verlustrechnung von Corcept Therapeutics Incorporated

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

MGK offers lower costs and mega-cap stability; SLYG delivered 27.4% returns over one year with broader diversification across industrials and healthcare.

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.

Handelsbanken Fonder AB grew its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 28.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,881 shares of the biotechnology company's stock after purchasing an additional 8,100 shares during the quarter. Handelsbanken Fonder

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.

FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 322,370 shares of the biotechnology company's stock after buying an additional 12,352 shares during

Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company's stock after buying an additional 8,000 shares during the period.

Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.

Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.